Not for everyone
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia
With & Without Insurance: Most insurance accepted plus affordable self-pay options for uninsured patients
These pharmacological agents exhibit beneficial effects on glycemic regulation, weight management, and cardiovascular outcomes, thereby establishing their essential roles in contemporary diabetes management [3-5]
Liraglutide also showed a beneficial effect, though less pronounced, with an 18% reduced risk